Kura Oncology Commercial Chief Sells 32,450 Shares

Two sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026; another was a tax-related sell-to-cover associated with RSU vesting.

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported selling 32,450 shares of common stock in three transactions on September 28 and 29, 2026. He sold 9,020 shares at $10.4973 per share on September 28 as a sell-to-cover for taxes associated with RSU vesting. He also sold 8,000 shares on September 28 at a weighted-average price of $10.5622 and 15,430 shares on September 29 at a weighted-average price of $10.7487. The latter two sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026.

Insider Trade Summary

Net Seller: 32,450 shares

Net Sell 3 txns

Insider Powl Brian T.

Role Chief Commercial Officer

Sold 32,450 shs ($345K)

Type	Security	Shares	Price	Value
Sale	Common Stock F4, F5	15,430	$10.7487	$166K
Sale	Common Stock F1	9,020	$10.4973	$95K
Sale	Common Stock F2, F3	8,000	$10.5622	$84K

Holdings After Transaction: Common Stock — 136,819 shares (Direct)

Footnotes (5)

1. F1. Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25.
2. F2. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2025. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
3. F3. This transaction was executed in multiple trades at prices ranging from $10.40 to $10.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
5. F5. This transaction was executed in multiple trades at prices ranging from $10.55 to $10.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares sold: 32,450 shares Shares sold: 9,020 shares Sale price per share: $10.4973 +4 more

7 metrics

Total shares sold 32,450 shares Three reported sales on September 28 and 29, 2026

Shares sold 9,020 shares September 28, 2026

Sale price per share $10.4973 9,020-share sale on September 28, 2026

Shares sold 8,000 shares September 28, 2026

Weighted-average sale price per share $10.5622 8,000-share sale on September 28, 2026

Shares sold 15,430 shares September 29, 2026

Weighted-average sale price per share $10.7487 15,430-share sale on September 29, 2026

Key Terms

sell-to cover, restricted stock units, Rule 10b5-1 trading plan, weighted average sale price

4 terms

sell-to cover financial

"Sell-to cover for taxes associated with the vesting of an RSU"

restricted stock units financial

"acquired by the Reporting Person upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"sales reported herein were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Chief Commercial Officer Brian T. Powl sell?

Brian T. Powl reported selling 32,450 shares in three transactions. He sold 9,020 shares on September 28, 2026, at $10.4973 per share; 8,000 shares that day at a weighted-average $10.5622 per share; and 15,430 shares on September 29 at a weighted-average $10.7487 per share.

What price ranges were reported for Brian T. Powl’s KURA sales?

The 8,000-share sale on September 28, 2026, was executed in multiple trades at prices from $10.40 to $10.70, with a reported weighted-average price of $10.5622 per share. The 15,430-share sale on September 29 was executed from $10.55 to $10.90, with a weighted average of $10.7487 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 06:30 PM Accepted by SEC EDGAR 09/29/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Powl Brian T.

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		S(1)		9,020	D	$10.4973	160,249	D
Common Stock	09/28/2026		S(2)		8,000	D	$10.5622(3)	152,249	D
Common Stock	09/29/2026		S(4)		15,430	D	$10.7487(5)	136,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25.

2. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2025. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.

3. This transaction was executed in multiple trades at prices ranging from $10.40 to $10.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.

5. This transaction was executed in multiple trades at prices ranging from $10.55 to $10.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair, Attorney-in-fact for Brian Powl	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)